3rd Quarter - Report
W STRATEGIES, LLC for ACTELION PHARMACEUTICALS US, INC
Firm
Income
$30,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Education about the importance of access to innovative drug therapies. H.R.2430/S.934: FDA Reauthorization Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.